<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04661358</url>
  </required_header>
  <id_info>
    <org_study_id>DRCR.net Protocol AF</org_study_id>
    <secondary_id>U10EY014231</secondary_id>
    <nct_id>NCT04661358</nct_id>
  </id_info>
  <brief_title>Fenofibrate for Prevention of DR Worsening</brief_title>
  <acronym>Protocol AF</acronym>
  <official_title>A Randomized Clinical Trial Evaluating Fenofibrate for Prevention of Diabetic Retinopathy Worsening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Eye Institute (NEI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leona M. and Harry B. Helmsley Charitable Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized trial will evaluate the effect of fenofibrate compared with placebo for&#xD;
      prevention of diabetic retinopathy (DR) worsening through 4 years of follow-up in&#xD;
      participants with mild to moderately severe non-proliferative DR (NPDR) and no CI-DME at&#xD;
      baseline.&#xD;
&#xD;
      In addition to evaluating efficacy, this study aims to evaluate the feasibility of a model&#xD;
      for ophthalmologists to prescribe or collaborate with a primary care provider such as an&#xD;
      internist/endocrinologist to prescribe and monitor the drug safely. If this study&#xD;
      demonstrates that fenofibrate is effective for reducing the onset of proliferative diabetic&#xD;
      retinopathy (PDR) or and the results are adopted by the community of retina specialists, a&#xD;
      new strategy to prevent vision threatening complications of diabetes could be widely adopted.&#xD;
      Widespread use of an oral agent effective at reducing worsening of DR would decrease the&#xD;
      numbers of patients who undergo more invasive and much more expensive treatment for DR and&#xD;
      who are consequently at risk for side effects that adversely affect visual function. This&#xD;
      study will also assess the relationship of glycemic variability as measured by continuous&#xD;
      glucose monitoring with DR outcomes. Ancillary studies will characterize functional and&#xD;
      structural outcomes in this cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 5, 2021</start_date>
  <completion_date type="Anticipated">April 2027</completion_date>
  <primary_completion_date type="Anticipated">April 2027</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, double-masked, placebo-controlled clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Worsening of diabetic retinopathy</measure>
    <time_frame>4- years</time_frame>
    <description>Defined as&#xD;
3 or more step worsening in person-level Early Treatment Diabetic Retinopathy Study (ETDRS) diabetic retinopathy severity on fundus photographs.&#xD;
Development of neovascularization within the 7-modified ETDRS fields on fluorescein angiography in either eye.&#xD;
Intraocular procedure undertaken to treat diabetic retinopathy in either eye including panretinal photocoagulation, intraocular anti-vascular endothelial growth factor, corticosteroid, or vitrectomy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular procedure undertaken to treat diabetic retinopathy or diabetic macular edema in either eye including PRP, intraocular anti-VEGF, corticosteroid, focal/grid laser or vitrectomy</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of CI-DME in either eye</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as, either 1) at least a 10% increase in OCT central subfield thickness from baseline, OCT central subfield thickness greater than sex and machine-specific threshold values (Zeiss Cirrus: CST ≥290 µm in women or ≥ 305 µm in men; Heidelberg Spectralis: CST ≥305 µm in women or ≥320 µm in men), and Investigator determination that thickening cannot be attributed to any cause other than CI-DME, or 2)Non-topical DME treatment including focal/grid laser, intraocular anti-VEGF, intraocular corticosteroid, or vitrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of center-involved diabetic macular edema with vision loss in either eye</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as either 1) an increase in OCT central subfield thickness of 10% or more from baseline, OCT central subfield thickness greater than sex and machine-specific threshold values (Zeiss Cirrus: CST ≥290 µm in women or ≥ 305 µm in men; Heidelberg Spectralis: CST ≥305 µm in women or ≥320 µm in men), investigator determination that thickening cannot be attributed to any cause other than DME, and a decrease in visual acuity from baseline of 10 or more letters at a single visit or 5 to 9 letters at 2 consecutive visits at least 21 days apart with vision loss presumed to be from DME, non-topical DME or 2) treatment including focal/grid laser, intraocular anti-VEGF, intraocular corticosteroid, or vitrectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual acuity loss from any cause</measure>
    <time_frame>4 years</time_frame>
    <description>Defined as a decrease in visual acuity from baseline of 10 or more letters at a single visit or a 5 to 9-letter decrease at 2 consecutive visits at least 21 days apart in either eye regardless of whether vision loss is presumed to be from DME or any other cause in either eye</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">910</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Fenofibrate 160-mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 160mg</intervention_name>
    <description>Participants begin with a dose of 160mg fenofibrate taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.</description>
    <arm_group_label>Fenofibrate 160-mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants begin with a dose of 160mg placebo taken once daily with food. The dose may be adjusted during follow-up based on protocol guidelines.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria&#xD;
&#xD;
               1. Age &gt;= 18 and &lt; 80 years&#xD;
&#xD;
                  • Individuals &lt;18 years old are not being included because DR is so rare in this&#xD;
                  age group that the diagnosis of NPDR may be questionable. Individuals ≥80 years&#xD;
                  old are excluded to limit co-morbidities and mortality over this long-term trial.&#xD;
&#xD;
               2. Diagnosis of diabetes mellitus (type 1 or type 2)&#xD;
&#xD;
                  • Any one of the following will be considered to be sufficient evidence that&#xD;
                  diabetes is present, current regular use of insulin for the treatment of&#xD;
                  diabetes, current regular use of oral anti hyperglycemia agents for the treatment&#xD;
                  of diabetes, or documented diabetes by American Diabetes Association and/or the&#xD;
                  World Health Organization criteria.&#xD;
&#xD;
               3. Both eyes meet the study eye criteria listed below.&#xD;
&#xD;
               4. Able and willing to provide informed consent.&#xD;
&#xD;
               5. Able and willing to wear a continuous glucose monitoring (CGM) device (for United&#xD;
                  States participants only).&#xD;
&#xD;
          -  Eye level inclusion criteria:&#xD;
&#xD;
             6. Either (1) both eyes have mild to moderately severe NPDR (defined by ETDRS DR&#xD;
             severity level 35 to 47) or (2) one eye has mild to moderately severe NPDR and the&#xD;
             other eye has microaneurysms only (DR severity level 20).&#xD;
&#xD;
               -  Confirmation of DR severity level is required by both the investigator and&#xD;
                  central Reading Center grading of fundus photographs.&#xD;
&#xD;
                  7. Both eyes must have best-corrected E-ETDRS visual acuity letter score ≥79&#xD;
                  (approximate Snellen equivalent 20/25 or better) 8. Both eyes must have media&#xD;
                  clarity, pupillary dilation, and study participant cooperation sufficient to&#xD;
                  obtain adequate fundus photographs, fluorescein angiogram, and OCT.&#xD;
&#xD;
               -  Investigator must verify accuracy of OCT scan by ensuring it is centered and of&#xD;
                  adequate quality (including segmentation line placement)&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               1. A condition that, in the opinion of the investigator, would preclude&#xD;
                  participation in the study (e.g., unstable medical status that may preclude&#xD;
                  successful completion of follow-up).&#xD;
&#xD;
               2. Initiation of intensive insulin treatment (a pump or multiple daily injections)&#xD;
                  within 3 months prior to screening or plans to do so in the next 3 months.&#xD;
&#xD;
               3. Participation in an investigational trial that involved treatment within 30 days&#xD;
                  of screening with any drug that has not received regulatory approval for the&#xD;
                  indication being studied.&#xD;
&#xD;
               4. Known allergy or hypersensitivity to any component of fenofibrate.&#xD;
&#xD;
               5. Known allergy to fluorescein dye.&#xD;
&#xD;
               6. History of treatment with a prescription fibrate medication (e.g. bezafibrate,&#xD;
                  fenofibrate, gemfibrozil, fenofibric acid) within 12 months prior to screening or&#xD;
                  anticipated need for fibrate medication for another indication (e.g. lipid&#xD;
                  management).&#xD;
&#xD;
               7. Any prior systemic treatment for DME or DR.&#xD;
&#xD;
               8. Decreased renal dysfunction, defined as requiring dialysis or central laboratory&#xD;
                  eGFR value &lt; 60&#xD;
&#xD;
               9. Active liver disease, defined as any liver function test &gt;3x upper limit of&#xD;
                  normal based on central laboratory value.&#xD;
&#xD;
              10. Pre-existing symptomatic gallbladder disease including gallstones; however, prior&#xD;
                  gallbladder removal is not an exclusion.&#xD;
&#xD;
              11. Triglycerides &gt;400mg/dL on treatment or &gt;700mg/dL on no treatment based on&#xD;
                  central laboratory value.&#xD;
&#xD;
              12. Current use of any of the following medications:&#xD;
&#xD;
                    -  Coumarin anticoagulants (Coumadin/Warfarin).&#xD;
&#xD;
                    -  Immunosuppressants that affect kidney function, such as cyclosporine and&#xD;
                       tacrolimus&#xD;
&#xD;
                    -  Colchicine (Colcrys)&#xD;
&#xD;
              13. History of severe myalgia requiring discontinuation of lipid lowering treatment.&#xD;
&#xD;
              14. Blood pressure &gt; 160/100 (systolic above 160 or diastolic above 100).&#xD;
&#xD;
              15. HbA1c &gt; 11.0% based on central laboratory value or if lab sample cannot be&#xD;
                  analyzed, recent result within 3 months&#xD;
&#xD;
              16. Systemic anti-VEGF or pro-VEGF treatment within 4 months prior to screening or&#xD;
                  anticipated use during the study.&#xD;
&#xD;
              17. For women of child-bearing potential: pregnant or lactating or intending to&#xD;
                  become pregnant within the next 4 years.&#xD;
&#xD;
              18. Participant is expecting to move out of the area of the clinical center to an&#xD;
                  area not covered by another clinical center during the next four years.&#xD;
&#xD;
                  The following exclusions apply to both eyes:&#xD;
&#xD;
              19. Evidence of definite neovascularization according to the investigator or central&#xD;
                  Reading Center grading of fluorescein angiography.&#xD;
&#xD;
                  • Includes presence of neovascularization (NV) outside of the 7-modified ETDRS&#xD;
                  fields on ultra-widefield imaging, which is an exclusion.&#xD;
&#xD;
              20. Current CI-DME based on clinical exam or OCT central subfield thickness (CST),&#xD;
                  defined as:&#xD;
&#xD;
                    -  Zeiss Cirrus: CST ≥290 µm in women or ≥ 305 µm in men.&#xD;
&#xD;
                    -  Heidelberg Spectralis: CST ≥ 305 µm in women or ≥320 µm in men.&#xD;
&#xD;
              21. Major non-diabetic intraocular pathology that in the opinion of the investigator&#xD;
                  would substantially and adversely affect visual acuity or lead to ocular&#xD;
                  neovascularization during the study.&#xD;
&#xD;
              22. Any prior treatment for DME or DR.&#xD;
&#xD;
              23. History of major ocular surgery within prior 4 months or anticipated within the&#xD;
                  next 6 months following randomization.&#xD;
&#xD;
              24. Anticipated need for intraocular anti-VEGF or PRP in the next 6 months following&#xD;
                  randomization.&#xD;
&#xD;
              25. History of intraocular anti-VEGF or corticosteroid treatment within the prior&#xD;
                  year for any indication.&#xD;
&#xD;
              26. Any history of vitrectomy.&#xD;
&#xD;
              27. History of YAG capsulotomy performed within 2 months prior to screening.&#xD;
&#xD;
              28. Aphakia.&#xD;
&#xD;
              29. Evidence of uncontrolled glaucoma (intraocular pressure must be &lt;30, with no more&#xD;
                  than one topical glaucoma medication, and no documented glaucomatous field loss&#xD;
                  for the eye to be eligible)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Y Chew, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Adam R Glassman, MS</last_name>
    <phone>813-975-8690</phone>
    <email>drcrnet@jaeb.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Emily Chew, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kent W. Small, MD, AMC</name>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <zip>91203-1971</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kent W Small, MD, AMC</last_name>
      <phone>818-552-5040</phone>
      <email>shayafadi@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Loma Linda University</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David I. Sierpina, MD</last_name>
      <phone>909-558-2169</phone>
      <email>nborntrager@llu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Ophthalmic Research Institute</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avtar T Ghuman, MD</last_name>
      <phone>239-939-4323</phone>
      <email>eileenk@eye.md</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute, James A. Staman, MD, PA- Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin J Thomas, MD</last_name>
      <phone>904-997-9202</phone>
      <email>kareny@floridaretinainstitute.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Florida Retina Consultants</name>
      <address>
        <city>Lakeland</city>
        <state>Florida</state>
        <zip>33805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M. Friedman, MD</last_name>
      <phone>863-682-7474</phone>
      <email>Dfagan@frc2020.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Vitreous Consultants, LLP</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34233-1261</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John H. Niffeneger, MD</last_name>
      <phone>941-924-0303</phone>
      <email>dscully@retinasarasota.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc H Levy, MD, FACS</last_name>
      <phone>941-921-5335</phone>
      <email>srqresearch@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marietta Eye Clinic</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annal D Meleth, MD, MS</last_name>
      <phone>678-803-2600</phone>
      <email>cnkemka@mariettaeye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Thomas Eye Group</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul L. Kaufman, MD</last_name>
      <phone>404-256-1507</phone>
      <email>kathyw@thomaseye.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Illinois Retina Associates SC - Oak Park Site</name>
      <address>
        <city>Oak Park</city>
        <state>Illinois</state>
        <zip>60304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew W MacCumber, MD, PhD</last_name>
      <phone>708-660-8450</phone>
      <email>saraw@illinoisretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>John Kenyon American Eye Institute, LLC</name>
      <address>
        <city>New Albany</city>
        <state>Indiana</state>
        <zip>47150</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Howard S Lazarus, MD</last_name>
      <phone>800-965-3937</phone>
      <email>ldavis@johnkenyon.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic-Cedar Rapids</name>
      <address>
        <city>Hiawatha</city>
        <state>Iowa</state>
        <zip>52233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul S Boeke, MD</last_name>
      <phone>319-362-8032</phone>
      <email>plee@wolfeclinic.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Elman Retina Group, P.A.</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael J. Elman, MD</last_name>
      <phone>410-686-3000</phone>
      <email>Starr@elmanretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George S Sharuk, MD</last_name>
      <phone>617-309-2520</phone>
      <email>Ann.Kopple@joslin.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul A Edwards, MD</last_name>
      <phone>313-874-9167</phone>
      <email>drush1@hfhs.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Center, PA DBA Retina Center of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdhish R Bhavsar, MD</last_name>
      <phone>612-871-2292</phone>
      <email>agilchrist@retinadocs.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute, LLC</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128-1729</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alia K. Durrani, MD</last_name>
      <phone>314-367-1181</phone>
      <email>rhonda.weeks@rc-stl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Surgeons of Central NY, PC</name>
      <address>
        <city>Liverpool</city>
        <state>New York</state>
        <zip>13088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin I. Rosenberg</last_name>
      <phone>315-445-8166</phone>
      <email>lsienkiewycz@rvscny.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Associates of Western NY, P.C.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620-4655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew T Witmer, MD</last_name>
      <phone>585-442-3411</phone>
      <email>myagoda@retinaassociatesofwny.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pamela Weber, MD/Island Retina</name>
      <address>
        <city>Shirley</city>
        <state>New York</state>
        <zip>11967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pamela Weber, MD, PC</last_name>
      <phone>631-924-4300</phone>
      <email>lswain@island-retina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dean A. McGee Eye Institute</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald M. Kingsley, MD</last_name>
      <phone>405-271-6307</phone>
      <email>Alisha-Brewer@dmei.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Verum Research LLC</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert O. Edwards, MD, PhD</last_name>
      <phone>541-762-2763</phone>
      <email>lcarroll@oregonretina.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants, LLC</name>
      <address>
        <city>Salem</city>
        <state>Oregon</state>
        <zip>97302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott M McClintic, MD</last_name>
      <phone>503-371-4350</phone>
      <email>dvetter@salemretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina-Vitreous Consultants, Inc.</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karl R. Olsen, MD</last_name>
      <phone>412-683-5300</phone>
      <email>merlottil@retinapittsburgh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southeastern Retina Associates, P.C.</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph M Googe, Jr, MD</last_name>
      <phone>865-588-0811</phone>
      <email>koliver@seretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Texas, PA</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles C. Wykoff, MD, PhD</last_name>
      <phone>713-524-3434</phone>
      <email>ilsa.ortega@retinaconsultantstexas.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, Baylor Eye Physicians and Surgeons</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Y. Weng, MD, MBA</last_name>
      <phone>713-798-3493</phone>
      <email>Becky.Chatham@bcm.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel Shami, MD</last_name>
      <phone>806-792-0066</phone>
      <email>ysaldivar@texasretina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darrell E. Baskin, MD</last_name>
      <phone>210-615-1311</phone>
      <email>ladams@retinasanantonio.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 3, 2020</study_first_submitted>
  <study_first_submitted_qc>December 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fenofibrate</keyword>
  <keyword>non-proliferative diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

